earnings
confidence high
sentiment positive
materiality 0.70
Cytek sees Q4 rev $62M (+8% YoY); FY2025 rev ~$201M
Cytek Biosciences, Inc.
- Preliminary Q4 2025 revenue of ~$62M, up 8% YoY and 19% QoQ.
- Full-year 2025 revenue estimated at ~$201M.
- CEO cites strong Services, Reagents and APAC instrument growth; EMEA returns to positive instrument sales.
- Company to present at JP Morgan Healthcare Conference on Jan 14, 2026.
- Full Q4 and FY results with 2026 guidance expected late February 2026.